Title: Cost effective drug response & Analysis of patients of “Chronic Myeloid Leukaemia” (CML) (Research period- 2015-2022)
Author: Dr Poonam Gupta -M.B.B.S- MD (Oncology)
DOI: https://dx.doi.org/10.18535/jmscr/v10i6.11
Abstract
CML is “clonal hematopoietic disorder” caused by an acquired genetic defect in pluripotent stem cell, which is BCR –ABL protein which results from a reciprocal translocation involving chromosome 9 and 22 .The definite diagnosis of CML is obtained by demonstrating the presence of a BCR-ABL1 fusion. The cornerstone of CML treatment is represented by the use of TKIs utilized as monotherapy. The prognosis for CML changed so much with the introduction of cost effective drug “imatinib”, that today CML-related deaths are rare and a normal life expectancy is possible for CML patients.
References
- Rebora P, Czene K, Antolini L, et al. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 2010;172(9):1028–1033.
- Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;142:1497
- Gambacorti-Passerini C. Part I: milestones in personalised medicine—imatinib. Lancet Oncol 2008;9(6):600.
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031–1037.
- Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103(7):553
- Branford S. Molecular monitoring in chronic myeloid leukemia-how low can you go? Hematology Am Soc Hematol Educ Program 2016;2016(1):156–163.
- Viganò I, Di Giacomo N, Bozzani S, et al. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis. Am J Hematol 2014;89(10):E184–E187.
- Gambacorti-Passerini C, Piazza R. Imatinib—a new tyrosine kinase inhibitor for first-line treatment of chronic myeloid leukemia in 2015. JAMA Oncol 2015;1(2):143–144. 67. O’Brien S, Berman E, Moore JO, et al. NCCN Task Force report
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
- Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol 2011;18:89–97.
- Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104:155–163.
- Gale RP, Hehlmann R, Zhang MJ, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 1998;91:1810–1819. 151. Enright H, Daniels K, Arthur DC, et al. Related donor marrow transplant